// App-Quantinova.ai

271 : Efficacy of MAU868, a Novel BKV Neutralizing Monoclonal Antibody (mAb), for the Treatment of Severe BK Virus Nephropathy (BKVN) After Kidney Transplant

Researchers

Presenter

  • S. C. Jordan

Principal Investigators

  • N. Ammerman

  • M. Toyoda

  • K. Lim

  • J. R. Abend

  • A. Patick

  • M. R. Hodges

  • A. Vo

  • S. J. Kovacs

Medical Centers

  • Comprehensive Transplant Center, Cedars Sinai Medical Ctr, West Hollywood, CA

  • Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA

  • Cedars-Sinai Medical Center, Los Angeles, CA

  • Novartis Institutes for BioMedical Research, Virology Research, Emeryville, CA

  • Amplyx Pharmaceuticals, San Diego, CA

  • Novartis Institutes for BioMedical Research, Translational Medicine, East Hanover, NJ

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Pulmonary/Respiratory Diseases

  • Nephrology

Disease

  • Idiopathic pulmonary fibrosis

  • BK virus nephropathy

  • Pulmonary fibrosis

  • Renal disease

  • End stage renal disease

Biomarkers

  • N/A

Drug/Treatment

  • IVIG

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved